Welcome to our dedicated page for Zomedica news (Ticker: ZOM), a resource for investors and traders seeking the latest updates and insights on Zomedica stock.
Zomedica Corp. develops and commercializes animal-health diagnostic and therapeutic device products for equine and companion-animal care. Company news commonly covers expansion of the TRUFORMA point-of-care diagnostic menu, including equine endocrine and reproductive assays, and updates for therapeutic brands such as PulseVet, Assisi, Calmer Canine, EquiLoop, and VETIGEL.
Recurring updates also address product launches, veterinary monitoring technology such as the VETGuardian Zero Touch monitor, distribution arrangements for international markets, investor webinars, financial results, and the development-services segment tied to engineering, contract manufacturing, and intellectual-property licensing.
Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) has priced a public offering of 187.5 million common shares and short-term warrants at $0.16 each, targeting approximately $30 million in gross proceeds. The offering is expected to close around July 7, 2020, pending customary conditions. Funds will primarily support the development of the TRUFORMA™ diagnostic platform and may also be used for potential repurchases of Series 1 Preferred Shares. H.C. Wainwright & Co. is the placement agent. The offering is not available to Canadian residents.
Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) has announced a public offering of its common shares and warrants, all to be sold by the company. The offering is subject to market conditions, and its specific terms, including size and completion timing, are not guaranteed. Proceeds will primarily support development of the TRUFORMA™ diagnostic platform, including milestone payments under existing agreements and general corporate needs. H.C. Wainwright & Co. is the exclusive placement agent. The offering will not be available to Canadian residents.
Zomedica Pharmaceuticals Corp. has appointed Robert Cohen as its new Interim Chief Executive Officer, effective immediately. Cohen brings over 15 years of experience in the medical device and biotech industries, including a proven track record in launching medical devices. He will lead the completion and commercial launch of Zomedica's TRUFORMA™ diagnostic platform. Former interim CEO, Shameze Rampertab, remains as Chief Financial Officer. The company has raised over $30 million under Rampertab's leadership, supporting its development and commercialization efforts.
Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced a public offering of 133.3 million common shares and warrants at $0.15 each, aiming to raise approximately $20 million before expenses. The offering is set to close around May 29, 2020, and is managed by H.C. Wainwright & Co. Funds will be used for the development of Zomedica's TRUFORMA™ diagnostic platform and other general corporate purposes. The offering is detailed under SEC registration statement File No. 333-238322, and the securities are not available to Canadian residents.
Zomedica (NYSE American: ZOM) has completed verification of three additional assays for its TRUFORMA™ diagnostic platform, focusing on canine and feline thyroid and adrenal diseases. This includes two newly verified assays for feline total T4 and canine and feline TSH. The TRUFORMA™ platform is designed for rapid diagnosis with results in under 20 minutes, utilizing innovative Bulk Acoustic Wave technology. Zomedica’s completion of these assays positions it uniquely in a market projected to grow from $2 billion in 2019 to $2.7 billion by 2027, addressing significant unmet needs in veterinary diagnostics.
Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) reported a consolidated net loss of $2,450,618, or $0.02 per share, for Q1 2020, a significant improvement from the loss of $11,676,908, or $0.12 per share in Q1 2019. Research and development expenses saw a dramatic decrease of 92% to $630,066 due to reduced milestone payments. General and administrative expenses dropped by 61% to $1,248,861. The company’s cash position improved to $1,496,752 as of March 31, 2020, up from $510,586 in Q4 2019, mainly due to financing activities. Zomedica remains focused on its TRUFORMA™ diagnostic platform.